"Ensuring our crisis canines are healthy is our number one priority. Throughout my career in veterinary oncology, I have seen how earlier cancer detection can improve patient outcomes and also improve the quality of life of the dog and its owner.
"The Nu.Q® Vet Cancer Test is intended for use during regular preventive check-ups of older dogs (seven years and older) or for younger dogs of high-risk breeds and we were delighted to offer the Nu.Q® Test to our crisis response canines at our annual meeting.
"Providing this additional screening tool allows our HOPE AACR dogs to continue to help people in their time of need."
Dr. Tom Butera, Chief Executive Officer, Volition Veterinary , added:
"We were delighted to be able to sponsor HOPE AACR's event through donating the Nu.Q® Vet Cancer Test. The screening test is accessible, affordable, and easy-to-use.
"Many of the crisis canines we saw are 'high-risk' breeds, such as golden retrievers, German shepherds, beagles, and so on. Being able to offer the test to the dogs that bring comfort in challenging times, has been such a privilege.
"I'd like to thank Dr. Michelle Silver and her team for collecting and processing the Nu.Q® Vet Cancer Test samples. We'd also like to thank Drucker Diagnostics for providing a centrifuge to help us process samples."
Sylvia Zborowski, Co Regional Manager, Northeast HOPE AACR, shared:
"Our mission is to provide comfort and encouragement through animal-assisted support to individuals affected by crises and disasters. We have been serving people affected by disasters and traumatic events, free of charge, since 1999.
"Our annual conference was a great opportunity to educate our members about early cancer screening and we are grateful to Volition for their support."
Learn More About the Nu.Q® Vet Cancer Test
Educating the veterinary community about early cancer detection is important. Join a free DVM360 webinar to hear from world-renowned veterinary oncologist, Dr Sue Ettinger, aka, Dr Sue Cancer Vet, about the clinical evidence supporting Nu.Q® Vet, how to process a sample, interpret results, and communicate them to pet parents, and how to understand and integrate the test into your practice.
Details of the Webinar: Utilizing the Nu.Q® Vet Cancer Test in Practice
Registration link
About HOPE AACR:
HOPE Animal-Assisted Crisis Response has about 300 teams that respond to disasters such as man-made trauma, natural disasters, debriefs and more.
Would you like donate to HOPE AACR? HOPE AACR are an all-volunteer non-profit organization. All donations and support go towards defraying costs associated with training and certifying new crisis teams, developing training programs and materials, and helping to reduce the out-of-pocket expenses our members incur when they deploy.
About the Nu.Q® Vet Cancer Test
The Nu.Q® Vet Cancer Test is intended for use during regular preventive check-ups of older dogs (seven years and older) or for younger dogs of high-risk breeds. The Nu.Q® Vet Cancer Tests is non-invasive and cost-effective. The test is available in over 20 countries, including the USA, UK, Germany, Poland, Spain, Japan, and more. More than 100,000 tests were sold in 2024.
About Volition
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, [email protected] +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, [email protected], +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
Video : https://www.youtube.com/watch?v=ivkD4YWK3QE
SOURCE VolitionRx Limited
Share this article